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Abstract
Backgound: Endometrial mixed carcinoma with the neuroendocrine carcinoma (NEC) component is rare and is
believed
to have a poor prognosis. CD10 expression is reported to be a favorable prognostic marker for some tumors such
as B-lymphoblastic leukemia/lymphoma, but unfavorable for others. Here, we report the case of a 33-year-old woman
diagnosed with endometrial mixed carcinoma with the NEC component expressing CD10 who showed a
favorable outcome.
Case presentation: The patient presented with lumbago and brownish discharge from the genitals. Imaging
modalities revealed a large exophytic mass in the uterine corpus, and a small one in the uterine cervix.
Radical hysterectomy with bilateral salpingo-oophorectomy was performed. Microscopic examination
of the endometrial and cervical masses revealed that the NEC component accounted for the maximum area in
both masses. However, small areas in both lesions showed well differentiated endometrioid adenocarcinoma
(WDEA) components, and histological transition between the two components was also observed. In addition
to CD56 and synaptophysin expression, the NEC component was positive for CD10 but negative for estrogen
receptor (ER), progesterone receptor (PgR), and carcinoembryonic antigen (CEA). In contrast, the WDEA component
expressed both ER and PgR, but neither CD10 nor neuroendocrine markers were demonstrated. The CD10 and
neuroendocrine markers clearly distinguished between the NEC and WDEA components. Furthermore, retained
expression of phosphatase and tensin homolog (PTEN) and weak phosphorylated Akt expression were found, which
were assumed to suppress the aggressive behavior of the tumor. The patient received postoperative chemotherapy
and has survived without recurrence for 6 years after the operation.
Conclusion: This is the first case of endometrial mixed carcinoma with the NEC component expressing CD10 that
showed a long survival.
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Background
Endometrial mixed carcinoma has recently been de-
fined as a new entity of gynecological carcinoma. It is
defined as a tumor composed of two or more histo-
logical types of endometrial carcinoma, at least one of
which is of the type II category [1]. Most common
mixed carcinomas consist of endometrioid and serous
carcinoma components, however, the prevalence of
mixed carcinoma with the neuroendocrine carcinoma
(NEC) component is very rare [1, 2]. Among mixed
carcinomas with the NEC component, the most com-
mon combination is with endometrioid adenocarcin-
oma (EA) [3, 4]. The prognosis of mixed carcinoma
correlates with the highest-grade component [1]. Be-
cause the prognosis for endometrial small cell NEC
and large cell NEC is poor [3, 4], it is considered that
the prognosis of mixed carcinoma with the NEC
component is unfavorable. Huntsman et al. reported
the clinicopathological findings of 16 cases of small
cell NEC, including 10 patients of mixed carcinoma
with small cell NEC component. Among these 10
cases, 6 patients died between 2 months and 4 years
postoperatively, 1 survived but exhibited multiple me-
tastases [2]. Furthermore, Mulvany and Allen reported
5 cases of large cell NEC including 4 patients of
mixed carcinoma with large cell NEC component
showing that half of the mix carcinoma patients died
within 2 years [5]. With regard to the association be-
tween clinical stage and prognosis of mixed carcin-
oma with small cell NEC component, Katahira et al.
reviewed the literature and found that only 23 % of
patients with International Federation of Gynecology
and Obstetrics (FIGO) stage I died within 5 years,
whereas 73 % of patients with stage II-IV died within
2 years [6]. Although the prognosis of endometrial mixed
carcinoma with the NEC component is regarded as poor,
especially advanced FIGO stage, very small number of
long survival cases was reported [2, 7–9]. Half of the long
surviving cases were early FIGO stage, however, the other
factor (s) that may influence or correlate with favorable
prognosis remain unclear.
CD10 is a cell-surface neutral endopeptidase and is dis-
tributed ubiquitously in various tissues. It is associated
with multiple biological functions such as cellular prolifer-
ation, migration, differentiation and stem cell maintenance
[10]. CD10 is expressed in several malignancies and
through these functions CD10 is associated with biological
properties of cancer including invasion, metastasis, and
sensitivity to chemotherapy [10]. CD10 expression is a
good prognostic marker in B-lymphoblastic leukemia/
lymphoma [11], uterine cervical cancer [12], and non-
small cell lung cancer [13]. On the other hand, it is a poor
prognostic marker in several cancers such as gastric, pan-
creatic, colorectal carcinomas [14], melanoma [15], and
skin cancers [16]. The significance of CD10 expression in
endometrial mixed carcinoma with the NEC component
is currently unknown.
Here we report a case of endometrial mixed carcinoma
with the NEC component expressing CD10 at FIGO stage
II. By immunohistochemistry, retained expression of phos-
phatase and tensin homolog (PTEN) and weak phosphor-
ylated Akt expression were found in the NEC component,
which may contribute to suppress the aggressive behavior
of the tumor. The patient is alive without tumor recur-
rence for 6 years after surgery. To the best of our know-
ledge, this is the first case indicating the association
between CD10 expression and favorable outcomes of
mixed carcinoma with the NEC component.
Case presentation
A 33-year-old woman presented with lumbago and brown-
ish discharge from the genitals, which persisted for
3 months and continued to worsen. Physical examin-
ation and imaging modalities revealed exophytic tu-
mors located in the uterine cervix and uterine corpus.
As endometrioid carcinoma with neuroendocrine differen-
tiation was suspected on the basis of preoperative biopsy,
radical hysterectomy with bilateral salpingo-oophorectomy
was performed. The patient received postoperative chemo-
therapy and has exhibited no recurrence for 6 years
postoperatively.
Table 1 Primary antibodies used in this study
Marker Source Dilution Clone/code
AE1/AE3 Dako ×800 M3515
34β-E12 Dako ×200 M0630
CAM 5.2 Ventana diluted CAM 5.2
EMA Dako ×100 E29
CEA Dako ×150 II-7
ER Ventana diluted SP1
PgR Ventana diluted 1E2
CD10 Dako ×80 SS2/36
CD56 Novocastra ×100 B6
Chromogranin Dako ×100 DAK-A3
Synaptophysin Dako ×400 A0010
S-100 Dako ×2000 ER-PR8
p16 Abcam ×200 2D9A12
AKT1 Abcam ×100 ab54753
AKT1 (phospho S473) Abcam ×100 104A282
PTEN Abcam ×150 EPR9941
β-catenin Millipore ×500 E247
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Methods
Immunohistochemistry
Immunohistochemical staining was performed on
formalin-fixed and paraffin embedded tissues. Four-
micron sections were pretreated in citrate buffer
(pH 6.0) in a microwave oven for antigen retrieval.
The primary antibodies used in this study are shown
in Table 1. The primary antibody reaction was per-
formed at room temperature for 60 min, and the sig-
nal was detected using the LSAB 2 HRP system




The uterus along with both ovaries and fallopian tubes
weighed 225 g. On sectioning, large bulky tumors were
found in the uterine endometrium and uterine cervix
(Fig. 1). The endometrial tumor measured 40 × 40 mm
and showed deep invasion into the muscle layer. How-
ever, the serosal surface was not involved. The cervical
tumor measured 28 × 28 mm and infiltrated into the
uterine cervical stroma, but did not extend beyond the
uterus. Based on these findings, the patient’s postsurgical
stage was defined as FIGO stage II.
Microscopic findings
Most of the bulky and ill-defined masses from the endo-
metrium and cervix consisted of broad trabecular, solid
sheets and irregular gland-like structures of cancer cells
with vesicular nuclei, prominent nucleoli, and faintly
eosinophilic cytoplasm. Peripheral palisading and central
necrosis were apparent (Fig. 2a). These findings sug-
gested NEC. Mitotic figures were conspicuous at 5–12
per 10 high-power fields (HPF). The NEC cells of the
endometrial tumor invaded the myometrium to more
Fig. 1 Macroscopic characteristics of the tumors. Bulky and solid tumors with whitish color are observed in the fundus (※※) and cervix (※).
Large tumor (※※) arising from the endometrial mucosa of the fundus and invading the deep muscle layer. Small tumor (※) limited to the
cervical mucosa, with no muscle layer invasion
Fig. 2 Microscopic findings of the tumors. a: The NEC component shows solid sheets and irregular gland like structures with vesicular nuclei and
prominent nucleoli. Necrosis and rosette formation are noted. b: The WDEA component shows irregular tubular structures with cribriform pattern
and complex folds. c: Histological transition is observed at the boundary between the NEC and WDEA components. Original magnification: a, b:
×200, c: ×100
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than half its depth. The NEC cells of the cervical tumor
infiltrated the cervical stroma, but did not reach the
muscle layer. Lymphovascular invasion was observed,
but no lymph node metastasis was identified. In small areas
of the endometrial and cervical tumors, the cancer cells
showed an atypical columnar shape with enlarged nuclei
located on the basal side, irregular tubular glands showing
a back-to-back structure, and complex fold formation.
Fig. 3 Immunohistochemical profile of the present case. a: The NEC component shows marked CD10 expression, whereas WDEA does not. b:
CD56 immunoreactivity is observed in the NEC component. c: ER expression is not detected in the NEC component, but strong ER expression is
demonstrated in the WDEA component. d: Neither the NEC component nor the WDEA component exhibits CEA expression. e: p16 is not noted
in the WDEA component. f: PTEN expression is weak but diffusely detected in the NEC component. g: Phosphorylated AKT is detected faintly in
the NEC component
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Solid nests of cancer cells occupied less than 5 % of both
lesions (Fig. 2b). These findings corresponded with well
differentiated endometrioid adenocarcinoma (WDEA).
Histological transition was observed at the boundary
between the NEC and WDEA components (Fig. 2c).
Immunohistochemistry revealed that the NEC compo-
nents in both endometrial and cervical tumors were
strongly immunoreactive for CD10, positive for CD56,
weakly positive for synaptophysin and p16, and negative
for estrogen receptor (ER), progesterone receptor (PgR),
carcinoembryonic antigen (CEA), and chromogranin
(Fig. 3a-e). The NEC component was also positive for
PTEN, comparable to the nuclear expression of stromal
cells, whereas phosphorylated Akt was observed weakly in
the cytoplasm (Fig. 3f, g). The WDEA components of both
endometrial and cervical tumors were positive for ER and
PgR, and negative for CD10, CD56, CEA, and p16
(Fig. 3a-e). The WDEA components of both tumors also
exhibited PTEN expression and weak phosphorylated Akt
expression. The results of the immunohistochemical
examination are summarized in Table 2.
Discussion
Because endometrial mixed carcinoma is a recently de-
fined category of WHO tumor classification [1], previous
studies reported the mixed carcinoma with NEC compo-
nent as NEC associated other neoplasm in a series of
small cell NECs or large cell NECs. We reviewed the lit-
erature and extracted 29 cases (Table 3). The mean age
of patients was 61 years (from 30 to 88), and the most
common histological combination was NEC and endo-
metrioid adenocarcinoma. The present case is the sec-
ond youngest and the longest survival case of this
carcinoma. Among the extracted cases, 12 died within
3 years and only 5 cases, including our patient, had
long-term survival of 3 years or more. These cases were
treated with different methods of therapy. One case was
treated only with surgery, two other cases underwent
chemotherapy in addition to surgery, and the remaining
cases were treated with a combination of surgery, radi-
ation and chemotherapy. We could not find a common
therapeutic regimen among the cases with long-term
survival. Albores-Saavedra et al. reported 5 cases of
polypoid small cell NEC including one mixed carcinoma
with NEC component and suggested that polypoid endo-
metrial NEC shows favorable prognosis [7]. In agreement
with their observation, our case also showed bulky lesions
of the endometrium and cervix, however, FIGO stage of
the present case was more advanced than that of the pre-
vious case (FIGO II versus FIGO IA). Matsumoto et al. re-
ported that the patient was still alive without the disease
4 years after the surgery despite recurrence, but the prog-
nostic factors that contributed to the positive outcome
were unknown [9].
The present case survived without tumor recurrence
for 6 years after the surgery despite exhibiting FIGO
stage II. As described earlier, the prognosis of endomet-
rial mixed carcinoma is correlated with the highest grade
component. The histological grading of NEC is an
important prognostic factor in non-gynecological sites.
Ki-67 labeling index and mitotic rate are currently used
for the grading of neuroendocrine tumors (carcinoid,
atypical carcinoid, small cell carcinoma, and large cell
carcinoma), and these factors are well correlated with
the prognosis [17, 18]. However, histological grading by
use of the Ki-67 labeling index and mitotic rate for the
uterine cervical NEC has not been demonstrated, be-
cause the prognostic outcome is poor regardless of the
histological grading [19–21]. Although several studies
have reported poor prognosis of endometrial NEC [2, 5,
6, 9, 22, 23], the effect of histological grade of NEC on
the prognosis was not clarified. The present case showed
5–12 mitotic counts/ 10HPF and the ratio corresponds
to neuroendocrine tumor grade 2 of the digestive system
[24]. The relatively low counts of mitotic figures in our
case may contribute to favorable prognosis, however,
further studies are necessary to establish the significance
of histological grade in NEC component in the endomet-
rial mixed carcinoma.
The present case showed strong CD10 expression in
the NEC component and also exhibited positive PTEN
















AKT1 (phospho S473) + +
PTEN + +
β-catenin - -
NEC and WDEA indicate neuroendocrine carcinoma and well differentiated
endometrioid adenocarcinoma, respectively
The intensity of immunohistochemical reactivity is expressed as ++representing
strong intensity, + representing positive but not strong reactivity and, −
representing negative
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expression and weak phosphorylated Akt expression.
With regards to molecular correlation between CD10
expression and favorable prognosis, CD10 is associated
with cancer through its inhibitory effect on cell
migration and proliferation [10]. The molecular mechan-
ism of these effects induced by CD10 is associated with
the cleavage and inactivation of fibroblast growth factor
2 (FGF2) [25] or direct binding with PTEN, leading to
Table 3 Clinical and pathological features of endometrial mixed carcinoma with NEC component in the lterature and in the
present case
Case Reference Year Age Stage Associated neoplasm Treatment Outcome
1 Tohya et al. [30] 1986 64 IIIb Endometrioid adenosquamous
carcinoma
Surgery AWD 3 months




3 Campo et al. [32] 1992 72 UK Poorly differentiated adenocarcinoma Radiotherapy DOD 6 months
4 Huntsman et al. [2] 1994 72 IIa Endometrioid adenocarcinoma Surgery, Radiotherapy AWD 13 months
5 Huntsman et al. [2] 1994 55 IV Endometrioid adenocarcinoma Radiotherapy, Chemotherapy DOD 12 months
6 Huntsman et al. [2] 1994 54 IVb Atypical complex hyperplasia Surgery DOD 12 months
7 Huntsman et al. [2] 1994 30 IVb Atypical complex hyperplasia Surgery LFU
8 Huntsman et al. [2] 1994 37 IVb Endometrioid adenocarcinoma Surgery LFU
9 Huntsman et al. [2] 1994 70 IIa Endometrioid adenocarcinoma Surgery DOD 1 year
10 Huntsman et al. [2] 1994 62 IIIa Endometrioid adenocarcinoma Surgery DOD 2 months
11 Huntsman et al. [2] 1994 59 Ic Endometrioid adenocarcinoma Surgery, Radiotherapy,
Chemotherapy
DOD 4 years
12 Huntsman et al. [2] 1994 58 IVb Endometrioid adenocarcinoma Surgery DOD 4 months
13 Huntsman et al. [2] 1994 53 IIb Endometrioid adenocarcinoma Surgery NED 2 months
14 van Hoeven et al. [22] 1995 59 I Adenocarcinoma Surgery AWD 2 years
15 van Hoeven et al. [22] 1995 62 I Adenocarcinoma Surgery AWD 1.5 years
16 Sekiguchi et al. [33] 1998 60 Ib Adenocarcinoma, Squamous cell
carcinoma
Surgery DOD 28 months
17 Katahira et al. [6] 2004 54 Ib Endometrioid adenocarcinoma,
Squamous
Surgery, Chemotherapy NED 28 months
cell carcinoma
18 Shaco-Levy et al. [34] 2004 79 UK Papillary serous carcinoma Surgery, Radiotherapy DOD 5 months
19 Mulvany and Allen [5] 2007 80 Ic Endometrioid adenocarcinoma Surgery DOD 5 months
20 Mulvany and Allen [5] 2007 77 IIb Endometrioid adenocarcinoma Surgery, Radiotherapy DOD 23 months
21 Mulvany and Allen [5] 2007 79 IIIa Endometrioid adenocarcinoma Surgery, Radiotherapy AWD 2 months
22 Mulvany and Allen [5] 2007 88 IIIc Endometrioid adenocarcinoma Surgery, Radiotherapy AWD 1 month
23 Albores-Saavedra et al. [7] 2008 66 Ia Endometrioid adenocarcinoma Surgery NED 4 years





25 Sato et al. [8] 2010 56 IVb Endometrioid adenocarcinoma Surgery, Chemotherapy DOD 3 years
26 Matsumoto et al. [9] 2011 44 IIIc Atypical complex hyperplasia Surgery, Radiotherapy,
Chemotherapy
NED 4 years
27 Koo et al. [36] 2014 52 Ia Endometrioid adenocarcnima,
Atypical
Surgery, Chemotherapy NED 15 months
complex hyperplasia
28 Koo et al. [36] 2014 63 Ib Endometrioid adenocarcnima,
Atypical
Surgery, Chemotherapy NED 5 months
complex hyperplasia
29 Current report case 2015 33 II Endometrioid adenocarcinoma Surgery, Chemotherapy NED 6 years
UK unknown, DOD dead on disease, AWD alive with disease, NED alive without evidence of disease, LFU lost to follow-up
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the enhancement of stability and activity, which result in
the inhibition of the Akt pathway [26]. These inhibitory
effects on cell migration and proliferation allow CD10 to
prevent the aggressive behavior of tumor cells [10, 26].
Therefore, we assume that CD10 expression in the NEC
component has an anti-cancer effect by retaining the
expression of PTEN, which leads to decreased phosphor-
ylated Akt expression. Although the NEC component is
usually considered as a poor prognostic factor, the
inhibitory effects of CD10 may have contributed to the
favorable outcome seen in the present case.
We were unable to identify any other study that ex-
amined the correlation between CD10 expression in
endometrial NEC and prognosis. As described earlier,
CD10 is a favorable prognostic marker in some tu-
mors such as B-lymphoblastic leukemia/lymphoma
[27, 28] but unfavorable in others [14]. Intriguingly,
the expression patterns of CD10 are correlated with
the prognosis of renal clear cell carcinoma. The apical
extracellular expression of CD10 shows better progno-
sis than cytoplasmic or intracellular membrane ex-
pression [29]. Because the prognostic value of CD10
may differ depending on the type of tissue from
which the tumor arises, further studies are necessary
to elucidate the significance of CD10 expression in
prognosis.
Conclusions
We reported a case of endometrial mixed carcinoma
with NEC component showing favorable prognosis des-
pite being FIGO stage II. Marked CD10 expression in
the NEC component was associated with a retained
expression of PTEN and a decreased expression of phos-
phorylated Akt, which may have resulted in anti-cancer
effects and contributed to the favorable prognosis.
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